 | Up a level |
Villa, Alessandro; De Mitri, Zemira; Vincenti, Simona; Crippa, Elisabetta; Castiglioni, Laura; Gelosa, Paolo; Rebecchi, Monica; Tosi, Delfina; Brunialti, Electra; Oevermann, Anna; Falleni, Monica; Sironi, Luigi; Bello, Lorenzo; Mazzaferro, Vincenzo; Ciana, Paolo (2024). Canine glioblastoma-derived extracellular vesicles as precise carriers for glioblastoma imaging: Targeting across the blood-brain barrier. Biomedicine & pharmacotherapy, 172, p. 116201. Elsevier 10.1016/j.biopha.2024.116201
Eshmuminov, Dilmurodjon; Studer, Debora J; Lopez Lopez, Victor; Schneider, Marcel André; Lerut, Jan; Lo, Mary; Sher, Linda; Musholt, Thomas Johannes; Lozan, Oana; Bouzakri, Nabila; Sposito, Carlo; Miceli, Rosalba; Barat, Shoma; Morris, David; Oehler, Helga; Schreckenbach, Teresa; Husen, Peri; Rosen, Charles B; Gores, Gregory J; Masui, Toshihiko; ... (2023). Controversy Over Liver Transplantation or Resection for Neuroendocrine Liver Metastasis: Tumor Biology Cuts the Deal. Annals of surgery, 277(5), e1063-e1071. Wolters Kluwer Health 10.1097/SLA.0000000000005663
Haber, Philipp K; Castet, Florian; Torres-Martin, Miguel; Andreu-Oller, Carmen; Puigvehí, Marc; Maeda, Miho; Radu, Pompilia; Dufour, Jean-Francois; Verslype, Chris; Czauderna, Carolin; Marquardt, Jens U; Galle, Peter R; Vogel, Arndt; Bathon, Melanie; Meyer, Tim; Labgaa, Ismail; Digklia, Antonia; Roberts, Lewis R; Mohamed Ali, Mohamed A; Mínguez, Beatriz; ... (2023). Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. Gastroenterology, 164(1), 72-88.e18. Elsevier 10.1053/j.gastro.2022.09.005
Vincenti, Simona; Villa, Alessandro; Crescenti, Daniela; Crippa, Elisabetta; Brunialti, Electra; Shojaei-Ghahrizjani, Fereshteh; Rizzi, Nicoletta; Rebecchi, Monica; Dei Cas, Michele; Del Sole, Angelo; Paroni, Rita; Mazzaferro, Vincenzo; Ciana, Paolo (2022). Increased Sensitivity of Computed Tomography Scan for Neoplastic Tissues Using the Extracellular Vesicle Formulation of the Contrast Agent Iohexol. Pharmaceutics, 14(12) MDPI 10.3390/pharmaceutics14122766
Kim, Richard D; Sarker, Debashis; Meyer, Tim; Yau, Thomas; Macarulla, Teresa; Park, Joong-Won; Choo, Su Pin; Hollebecque, Antoine; Sung, Max W; Lim, Ho-Yeong; Mazzaferro, Vincenzo; Trojan, Joerg; Zhu, Andrew X; Yoon, Jung-Hwan; Sharma, Sunil; Lin, Zhong-Zhe; Chan, Stephen L; Faivre, Sandrine; Feun, Lynn G; Yen, Chia-Jui; ... (2019). First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer discovery, 9(12), pp. 1696-1707. American Association for Cancer Research 10.1158/2159-8290.CD-19-0555
Lim, Ho Yeong; Merle, Philippe; Weiss, Karl Heinz; Yau, Thomas; Ross, Paul; Mazzaferro, Vincenzo; Blanc, Jean-Frédéric; Ma, Yuk Ting; Yen, Chia Jui; Kocsis, Judit; Choo, Su Pin; Sukeepaisarnjaroen, Wattana; Gérolami, René; Dufour, Jean-François; Gane, Edward J; Ryoo, Baek-Yeol; Peck-Radosavljevic, Markus; Dao, Thong; Yeo, Winnie; Lamlertthon, Wisut; ... (2018). Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with -Mutated Hepatocellular Carcinoma. Clinical cancer research, 24(19), pp. 4650-4661. American Association for Cancer Research 10.1158/1078-0432.CCR-17-3588
Bruix, Jordi; Tak, Won-Young; Gasbarrini, Antonio; Santoro, Armando; Colombo, Massimo; Lim, Ho-Yeong; Mazzaferro, Vincenzo; Wiest, Reiner; Reig, María; Wagner, Andrea; Bolondi, Luigi (2013). Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. European journal of cancer, 49(16), pp. 3412-3419. Elsevier 10.1016/j.ejca.2013.05.028
Bolondi, Luigi; Burroughs, Andrew; Dufour, Jean-François; Galle, Peter R; Mazzaferro, Vincenzo; Piscaglia, Fabio; Raoul, Jean Luc; Sangro, Bruno (2012). Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Seminars in liver disease, 32(4), pp. 348-59. New York, N.Y.: Thieme Medical Publishers 10.1055/s-0032-1329906
